Highlights of ACC 2024
Cardiology Update
APRIL 9, 2024
EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). Here is our curated list of the top sessions. New Engl J Med.
52 
Let's personalize your content